BiotechTube

TERN-601

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight or Obesity

Conditions

Overweight or Obesity

Trial Timeline

Mar 7, 2025 → Sep 19, 2025

NCT ID
NCT06854952

About TERN-601

TERN-601 is a phase 2 stage product being developed by Terns Pharmaceuticals for Overweight or Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT06854952. Target conditions include Overweight or Obesity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06854952Phase 2Completed

Competing Products

20 competing products in Overweight or Obesity

See all competitors
ProductCompanyStageHype Score
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
33
LY3305677 + PlaceboEli LillyPhase 1
33
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
33
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
33
Tirzepatide + AcetaminophenEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77
LY3437943 + PlaceboEli LillyPhase 1
33
LY3502970 + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
LY3541105 + PlaceboEli LillyPhase 1
33
Retatrutide + PlaceboEli LillyPhase 2
52
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
33
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
52
pramlintide acetate + sibutramine + phentermine + placeboAstraZenecaPhase 2
52

Other Products from Terns Pharmaceuticals

TERN-501 + TERN-101Phase 2
49
TERN-101Phase 2
49
TERN-701Phase 1/2
38
TERN-201Phase 1
30